May 10, 1994Biochemistry

Mechanistic Studies on Human Platelet Isoprenylated Protein Methyltransferase: Farnesylcysteine Analogs Block Platelet Aggregation without Inhibiting the Methyltransferase

View Full Paper

Ask AI

Bookmark

Population

Human platelets

Comparison

Farnesylcysteine analogs with bulky moieties vs Bona fide methyltransferase inhibitors

Design

Preclinical

Authors

YMYuting MaNanjing Forestry University YSYi-Qun Shi YLYoung Hee LimSeoul Medical Center

Discussion

Member takes

Implication

Hypothesis-generating for a methyltransferase-independent antiplatelet pathway; leaves open translation to in vivo models or human use.

Structured PICO

Population

Human platelets

Intervention

Farnesylcysteine analogs with bulky moieties (N-benzoyl-S-farnesyl-L-cysteine [BzFC] and N-pivaloyl-S-farnesyl-L-cysteine [PFC])

Comparator

Bona fide methyltransferase inhibitors (e.g., N-acetyl-S-farnesyl-L-cysteine [AFC])

Outcome

Inhibition of platelet aggregation and methyltransferase activitysurrogate

Farnesylcysteine analogs inhibit platelet aggregation through a mechanism independent of isoprenylated protein methyltransferase blockade, revealing a novel signal transduction target.

Cite This Study

Ma et al. (1994) studied this question.

synapsesocial.com/papers/6a88ee039bde6b77b67b376d https://doi.org/10.1021/bi00184a009

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Mechanistic Studies on Human Platelet Isoprenylated Protein Methyltransferase: Farnesylcysteine Analogs Block Platelet Aggregation without Inhibiting the Methyltransferase

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Mechanistic Studies on Human Platelet Isoprenylated Protein Methyltransferase: Farnesylcysteine Analogs Block Platelet Aggregation without Inhibiting the Methyltransferase

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider